Physician profile
Christopher Coad
NPI 1053315762
$5,383.70
in general payments reported to CMS, 2019-2025
24 companies · $1,099 in 2025
The $1,099 reported for 2025 was more than what 89% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,040 · 2020: $416 · 2021: $454 · 2022: $813 · 2023: $576 · 2024: $986 · 2025: $1,099.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,661.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,661.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $952.85 | 2019-2025 | Cequa, Xelpros |
| Allergan, INC. | $508.45 | 2019-2022 | |
| Rxsight INC | $470.77 | 2023-2024 | Rxsight Contact Lens, Rxsight Injector Cartridge, Rxsight Injector Handpiece |
| Sight Sciences, INC. | $447.52 | 2019-2023 | Tearcare System |
| Oyster Point Pharma, INC. | $427.95 | 2022-2025 | Tyrvaya |
| Johnson & Johnson Surgical Vision, INC. | $334.62 | 2019-2025 | Tecnis Iol |
| Bausch & Lomb Americas INC. | $327.25 | 2022-2025 | Vyzulta, Miebo, Xiidra |
| Tarsus Pharmaceuticals, INC. | $255.86 | 2024-2025 | Xdemvy |
| Harrow Eye, LLC | $199.12 | 2024-2025 | Vevye |
| Abbvie INC. | $194.10 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $176.57 | 2019-2022 | |
| Biotissue Holdings INC. | $164.88 | 2021-2025 | |
| Omeros Corporation | $125.00 | 2019 | |
| Ivantis, INC | $105.26 | 2021 | |
| Dompe US, INC. | $104.46 | 2024-2025 | Oxervate |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $96.16 | 2020 | |
| Carl Zeiss Meditec, INC. | $85.76 | 2020 | |
| Alcon Vision LLC | $83.41 | 2025 | Rocklatan |
| Amgen INC. | $68.51 | 2024-2025 | Tepezza |
| Shire North American Group INC | $64.39 | 2019 | |
| Kala Pharmaceuticals, INC. | $63.99 | 2021-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $62.43 | 2020-2021 | |
| Carl Zeiss Meditec USA, INC. | $43.18 | 2024 | Artevo 800 |
| Thea Pharma INC. | $21.21 | 2025 | Iyuzeh |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Coad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.